RxDoctor Payments Data

Rachel Davis

Optometrist · Asheville, NCNPI 1841479391

Payments from drug & device makers

$4,611in general payments, 2019–2025

Across 165 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Johnson & Johnson Vision Care, Inc.$746
  • Bausch & Lomb Americas Inc.$588
  • Sun Pharmaceutical Industries Inc.$482
  • Tarsus Pharmaceuticals, Inc.$251
  • Notal Vision, Inc.$241
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$2415%
  • Food & beverage$4,37095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,611 in reported general payments places this provider in the 85th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$111,806
Medicare patients
718
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$88,453
LumiganBimatoprost31$14,203
CequaCyclosporine13$10,128
Latanoprost234$3,494
Doxycycline Hyclate14$1,166
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha69$801
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$703
Prednisolone Acetate17$647
MoxifloxacinMoxifloxacin Hcl15$324
ErythromycinErythromycin Base11$130
Acyclovir13$120
Timolol Maleate15$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$202$102,65692 claims
Sun Pharmaceutical Industries Inc.Cequa$482$10,12813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →